← Leaderboards
Kenneth Alan Perkins
University Of Pittsburgh At Pittsburgh
$15,843,214
Attributed
$19,671,978
Total exposure
18
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$19,671,978 · 18
By mechanism
R01$5,689,483 · 6
U01$5,613,363 · 1
P50$4,681,895 · 3
UH3$1,562,048 · 1
R21$830,374 · 2
UH2$482,117 · 1
Top collaborators
- Nurulain T Zaveri4 shared
- Darlene H Brunzell3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Xiu Liu$2,175,700
- Marsha D Marcus$3,952,453
- Hilary A. Tindle$15,133,646
- Jennifer J Deberry$2,604,929
- Anthony R Caggiula$2,033,361
Others in their field
Top investigators on “Nicotine”
- Dorothy K Hatsukami · University Of Minnesota Twin Cities$52,725,890
- Stephen T Higgins · University Of Vermont &St Agric College$41,481,617
- Neal L Benowitz · University Of California San Francisco$28,140,951
- Caryn Lerman · University Of Southern California$26,022,644
- Stephen S Hecht · University Of Minnesota$25,906,702
- Marina R. Picciotto · Yale University$25,752,267
Research focus
NicotineSmoking CessationClinical ResearchSmokingPlacebosHuman SubjectTobacco AbusePsychological ReinforcementNicotine ReplacementReinforcerSmokerPharmaceutical PreparationsProceduresNicotine DependenceAbstinenceWithdrawalAffectResponseRelapseLeadClinical TrialsCigaretteDesignRewards
Grant awards (64)
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$99,995
U01 · FY2024 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$1,398,808
U01 · FY2023 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,107,278
U01 · FY2022 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,007,282
U01 · FY2021 · DA
Reinforcement-enhancing effects of NRT$231,000
R01 · FY2017 · DA · contact PI
Medication development of a novel therapeutic for smoking cessation$771,686
UH3 · FY2015 · TR
Reinforcement-enhancing effects of NRT$265,457
R01 · FY2015 · DA · contact PI
Medication development of a novel therapeutic for smoking cessation$790,362
UH3 · FY2014 · TR
Reinforcement-enhancing effects of NRT$269,500
R01 · FY2014 · DA · contact PI
Threshold Dose for Nicotine Discrimination in Cigarettes$212,101
R21 · FY2014 · DA · contact PI
Medication development of a novel therapeutic for smoking cessation$482,117
UH2 · FY2013 · TR
Early Human Screening for Medication Efficacy$260,333
P50 · FY2013 · CA · contact PI
Threshold Dose for Nicotine Discrimination in Cigarettes$201,648
R21 · FY2013 · DA · contact PI
Early Human Screening for Medication Efficacy$307,154
P50 · FY2012 · CA · contact PI
Reinforcement-enhancing effects of nicotine$227,250
R21 · FY2012 · DA · contact PI
Early Human Screening for Medication Efficacy$332,777
P50 · FY2011 · CA · contact PI
Reinforcement-enhancing effects of nicotine$189,375
R21 · FY2011 · DA · contact PI
Early Human Screening for Medication Efficacy$372,349
P50 · FY2010 · CA · contact PI
Behavioral Genetics of Mood-Induced Smoking$235,636
R03 · FY2010 · DA · contact PI
Early Human Screening for Medication Efficacy$355,369
P50 · FY2009 · CA · contact PI
Behavioral Genetics of Mood-Induced Smoking$233,255
R03 · FY2009 · DA · contact PI
Tobacco Smoking, Nicotine and Negative Affect Relief$211,964
R01 · FY2009 · DA · contact PI
Improved Human Screening of Cessation Medications$304,348
P50 · FY2008 · CA · contact PI
Tobacco Smoking, Nicotine and Negative Affect Relief$211,964
R01 · FY2008 · DA · contact PI
Improved Human Screening of Cessation Medications$369,113
P50 · FY2007 · CA · contact PI
Tobacco Smoking, Nicotine and Negative Affect Relief$216,290
R01 · FY2007 · DA · contact PI
Tobacco Smoking, Nicotine and Negative Affect Relief$222,750
R01 · FY2006 · DA · contact PI
Improved Human Screening of Cessation Medications$211,804
P50 · FY2006 · CA · contact PI
Soc. for Research on Nicotine & Tobacco Annual Meeting$57,185
R13 · FY2006 · DA · contact PI
Affect, Context, and Placebo Responses to Nicotine$259,875
R01 · FY2005 · DA
Improved Human Screening of Cessation Medications$205,635
P50 · FY2005 · CA
Soc. for Research on Nicotine &Tobacco Annual Meeting$58,561
R13 · FY2005 · DA
Affect, Context, and Placebo Responses to Nicotine$259,875
R01 · FY2004 · DA
Improved Human Screening of Cessation Medications$180,869
P50 · FY2004 · CA
Soc. for Research on Nicotine &Tobacco Annual Meeting$78,561
R13 · FY2004 · DA
SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL$327,410
R01 · FY2003 · DA
INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS$312,368
R01 · FY2003 · DA
Affect, Context, and Placebo Responses to Nicotine$260,750
R01 · FY2003 · DA
Soc. for Research on Nicotine &Tobacco Annual Meeting$84,871
R13 · FY2003 · DA
SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL$328,283
R01 · FY2002 · DA
INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS$313,711
R01 · FY2002 · DA
Affect, Context, and Placebo Responses to Nicotine$254,764
R01 · FY2002 · DA
Soc. for Research on Nicotine &Tobacco Annual Meetings$58,561
R13 · FY2002 · DA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$0
P50 · FY2002 · CA
CHRONIC &ACUTE TOLERANCE TO NICOTINE IN HUMANS--TOLERANCE DISSIPATION$0
M01 · FY2002 · RR
CHRONIC &ACUTE TOLERANCE TO NICOTINE IN HUMANS--TOLERANCE DISSIPATION$0
M01 · FY2002 · RR
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$348,824
P50 · FY2001 · CA
SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL$332,669
R01 · FY2001 · DA
INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS$319,766
R01 · FY2001 · DA
DISCRIMINATIVE STIMULUS EFFECTS OF NICOTINE$218,298
R01 · FY2001 · DA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$0
P50 · FY2001 · CA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$0
P50 · FY2001 · CA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$0
P50 · FY2001 · CA
CHRONIC &ACUTE TOLERANCE TO NICOTINE IN HUMANS--TOLERANCE DISSIPATION$0
M01 · FY2001 · RR
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$348,824
P50 · FY2000 · CA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$348,824
P50 · FY2000 · CA
SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL$332,078
R01 · FY2000 · DA
INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS$328,773
R01 · FY2000 · DA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$245,224
P50 · FY2000 · CA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$245,224
P50 · FY2000 · CA
Pilot--Nicotine replacement therapy effect on smoking reinforcement by genotype$245,224
P50 · FY2000 · CA
DISCRIMINATIVE STIMULUS EFFECTS OF NICOTINE$211,938
R01 · FY2000 · DA
DISCRIMINATIVE STIMULUS OF NICOTINE--DIFFERENCES BETWEEN SMOKERS/NONSMOKERS$3,034
M01 · FY2000 · RR
CHRONIC &ACUTE TOLERANCE TO NICOTINE IN HUMANS--TOLERANCE DISSIPATION$3,034
M01 · FY2000 · RR